• Hiroyuki Hashimoto, Hiroyuki Yamada, Maki Murata, and Norio Watanabe.
• Department of Pharmacoepidemiology, Kyoto University, Kyoto, Japan.
• Cochrane Db Syst Rev. 2025 Jan 29; 1 (1): CD014937CD014937.

BackgroundAcute kidney injury (AKI) is a well-known complication of critical illnesses, significantly affecting morbidity and the risk of death. Diuretics are widely used to ameliorate excess fluid accumulation and oliguria associated with AKI. Their popularity stems from their ability to reduce the energy demands of renal tubular cells by inhibiting transporters and flushing out intratubular casts. Numerous studies have assessed the effects of diuretics in the context of AKI prevention and treatment. However, a comprehensive systematic review addressing this topic has yet to be conducted.ObjectivesThis review aimed to explore the benefits and harms of diuretics for both the prevention and treatment of AKI.Search MethodsThe Cochrane Kidney and Transplant Register of Studies was searched up to May 2024 using search terms relevant to this review. Studies in the Register are identified through searches of CENTRAL, MEDLINE, and EMBASE, conference proceedings, the International Clinical Trials Registry Platform (ICTRP) Search Portal, and ClinicalTrials.gov.Selection CriteriaWe selected randomised controlled trials (RCTs) and quasi-RCTs in which diuretics were used to prevent or treat AKI.Data Collection And AnalysisTwo authors independently extracted data using standardised data extraction forms. Dichotomous outcomes were expressed as risk ratios (RR) with 95% confidence intervals (CI). Where continuous scales of measurement were used to assess the effects of treatment, the standardised mean difference (SMD) was used. The primary review outcomes for AKI prevention studies were the incidence of AKI and any use of kidney replacement therapy (KRT). For treatment studies, the primary outcome was any use of KRT. The certainty of evidence was assessed per outcome using the Grades of Recommendation, Assessment, Development and Evaluation (GRADE) approach.Main ResultsWe included 64 studies (83 reports, 9871 participants): 53 prevention studies (8078 participants) and 11 treatment studies (1793 participants). Studies were conducted in the following World Health Organization regions: the Americas (15), Eastern Mediterranean (9), Europe (25), South-East Asia (2), and the Western Pacific (13). Thirty-six studies were single-centre studies, 19 were multicentre, and the setting was unclear in nine studies. Diuretics were compared to placebo, no treatment or conventional therapy, saline solutions (isotonic or hypotonic), 5% dextrose, 5% glucose, Hartmann's solution, and Ringer's acetate. Overall, the risk of bias was low in one study, high in 19 studies, and of some concern in 41 studies. Three studies could not be assessed because they did not report any outcomes of interest. For AKI prevention, compared to control, diuretics may reduce the risk of AKI (38 studies, 5540 participants: RR 0.75, 95%, CI 0.61 to 0.92; I2 = 77%; low-certainty evidence) and probably reduce any use of KRT (32 studies, 4658 participants: RR 0.63, 95% CI 0.43 to 0.91; I2 = 0%, moderate-certainty evidence) and death (33 studies, 6447 participants: RR 0.73, 95% CI 0.59 to 0.92; I2 = 0%; moderate-certainty evidence). The use of diuretics may result in little or no difference in the need for permanent dialysis (2 studies, 956 participants: RR 0.52, 95% CI 0.08 to 3.47; I2 = 21%; low-certainty evidence), hypotension (7 studies, 775 participants: RR 1.27, 95% CI 0.87 to 1.86; I2 = 0%; low-certainty evidence) and hypokalaemia (6 studies, 1383 participants: RR 1.20, 95% CI 0.88 to 1.73; I2 = 43%; low-certainty evidence), and had uncertain effects on arrhythmias (13 studies, 3375 participants: RR 0.77, 95% CI 0.57 to 1.04; I2 = 53%; very-low certainty evidence). Diuretics may make little or no difference to changes in SCr within 30 days (8 studies, 646 participants: SMD 0.41, 95% CI -0.01, to 0.83; I2 = 82%; low-certainty evidence) but it was uncertain whether diuretics increased urinary output (8 studies, 1155 participants: SMD 1.87, 95% CI -0.20 to 3.95; I2 = 99%; very low-certainty evidence). For AKI treatment, diuretics may make little or no difference to any use of KRT (8 studies, 1275 participants: RR 0.93, 95% CI 0.83 to 1.04; I2 = 2%; low-certainty evidence) or death (14 studies, 2052 participants: RR 1.08, 95% CI 0.96 to 1.22; I2 = 0%; low-certainty evidence). Diuretics may increase hypotension (2 studies, 720 participants: RR 1.99, 95% CI 1.16 to 3.41; I2 = 90%; low-certainty evidence) and probably increase arrhythmias (6 studies, 1011 participants: RR 1.62, 95% CI 1.12 to 2.33; I2 = 0%; moderate-certainty evidence). Diuretics may result in little or no difference in hypokalaemia (3 studies, 478 participants: RR 1.52, 95% CI 0.70 to 3.31; I2 = 0%; low-certainty evidence). It was uncertain whether diuretics increased urinary output (3 studies, 329 participants: SMD 4.40, 95% CI -0.94 to 9.74; I2 = 99%; very low-certainty evidence). The need for permanent dialysis and changes in serum creatinine were not reported.Authors' ConclusionsWhen used for the prevention of AKI, diuretics may reduce the risk of AKI. However, our confidence in the effect estimate is limited. Diuretics probably reduce the incidence of KRT use, and we are moderately confident in the effect estimate. When used for the treatment of AKI, diuretics may make little or no difference to any use of KRT, and our confidence in the effect estimate is limited. More RCTs are needed to explore the role of diuretics for treating established AKI.Copyright © 2025 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

9 keywords...

hide…